Subscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.
PHOTO/NewTimesRwanda PHOTO/NewTimesRwandaRwanda’s Central Bank has maintained the Key Repo Rate at 4.5 per cent to encourage continued lending by banks to the private sector and individuals.This followed the quarterly Monetary Policy Committee (MPC) meeting, held on Wednesday, August 12 to review recent economic developments globally and nationally as well as potential interventionsThe central bank in its statement signed by Governor John Rwangombwa expressed optimism that the Rwandan economy will pick up in the second half as evidenced by the Composite Index of Economic Activities which showed increased activity in the local economy.The key repo rate is the maximum rate at which commercial banks invest their money at the central bank.The Central Bank in April revised downwards its Key Repo rate from 5 per cent to 4.5 per cent with an aim to spur lending to the private sector to support economic recovery following the pandemic.By leaving it relatively low, it leads banks to consider lending to the market which will consequently drive economic recovery. Increased supply and appetite to lend among banks could consequently lead to a reduction in rates.Related Namibian central bank says economy to shrink by 1.7 pct Kenya’s Central bank suspends issuance of new bank licences Namibian central bank says economy to shrink by 1.7 percent
Motorists are asked to use caution while traveling on the road and help make the areas safe for firefighters and other motorists. The Kenai National Wildlife Refuge is still under an open burn ban which Ranger Leah Eskelin detailed. FacebookTwitterEmailPrintFriendly分享The U.S. Fish and Wildlife Service is reopening the Lower Skilak boat ramp and campground along with Bottenintnin Lake day use area and the rest of Skilak Lake Road. Eskelin: “There still is a burn ban in effect so they are welcome to go out and use the facilities there, and enjoy themselves, especially since the fish are in, but they can’t have any warming fires or open fires in the area.” Smoke may be visible from time to time and snags, falling trees, and ash pits are significantly dangerous. Those areas have been closed since June 17 due to fire activity from the Card Street Fire. That still means no campfires even in established rings. Only flames that can be turned off may be used. The partial burn ban lift only applied to state, municipal, and private lands and the KNWR is federal lands. Although surrounding areas have seen improvement to drought conditions due to recent rains, precipitation has been spotty and fire danger remains high throughout much of the Refuge. There are still firefighting personnel and equipment working in the areas. There is still active fire in some areas of the Kenai River and along Skilak Lake.
CAMERON, Mo. – The drivers’ meeting for the 2019 season at US 36 Raceway and Bethany Speedway is set for 9 a.m. on Saturday, Jan. 5, 2019 at the Cameron Community Center.The drivers’ meeting is combined for both race tracks so drivers can get all their paperwork completed for both tracks if they choose to.The meeting will allow drivers and teams to register their car and reserve pit stalls for the upcoming season.Registration for the 2019 season for IMCA RaceSaver Sprint Cars, IMCA Modifieds and IMCA Sunoco Stock Cars is $60 and $50 for Karl Chevrolet Northern SportMods is $50. Pit stalls are $60 to reserve for the 2019 season.The meeting will also include a discussion on the updated 2019 general rules and teams can bring any questions they have.This is a great opportunity for drivers and teams to get a head start on the 2019 season. Snacks and coffee will be available for all in attendance.The Cameron Community Center is located at 915 N. Ashland Drive, Cameron, Mo., 64429.
These scans show a 62-year-old man with non-Hodgkin lymphoma, at left in December 2015, and three months after treatment with Kite Pharma’s experimental gene therapy at MD Anderson Cancer Center in Houston. The treatment, called CAR-T cell therapy, turns a patient’s own blood cells into specialized cancer killers. It worked in a study, with more than one third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday, Feb. 28, 2017. The scans are from a presentation by Drs. Fred Locke and Sattva Neelapu, provided by the American Society for Blood and Marrow Transplantation and Kite. (ASBMT/Kite Pharma via AP) In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company’s manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. The experimental gene therapy, called CAR-T cell, turns a patient’s own blood cells into specialized cancer killers and worked in the study, with more than one third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday, Feb. 28, 2017. (Kite Pharma via AP) An experimental gene therapy that turns a patient’s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nation’s first approved gene therapy.A hopeful sign: the number in complete remission at six months — 36 percent — is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well.“This seems extraordinary … extremely encouraging,” said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center.The worry has been how long Kite’s treatment would last and its side effects, which he said seem manageable in the study. Follow-up beyond six months is still needed to see if the benefit wanes, Herbst said, but added, “this certainly is something I would want to have available.”The therapy is not without risk. Three of the 101 patients in the study died of causes unrelated to worsening of their cancer, and two of those deaths were deemed due to the treatment.It was developed at the government’s National Cancer Institute and then licensed to Kite. The Leukemia and Lymphoma Society helped sponsor the study.Results were released by the company and have not been published or reviewed by other experts. Full results will be presented at the American Association for Cancer Research conference in April.The company plans to seek approval from the U.S. Food and Drug Administration by the end of March and in Europe later this year.The treatment involves filtering a patient’s blood to remove key immune system soldiers called T-cells, altering them in the lab to contain a gene that targets cancer, and giving them back intravenously. Doctors call it a “living drug” — permanently altered cells that multiply in the body into an army to fight the disease.Patients in the study had one of three types of non-Hodgkin lymphoma, a blood cancer, and had failed all other treatments. Median survival for such patients has been about six months.Kite study patients seem to be living longer, but median survival isn’t yet known. With nearly nine months of follow-up, more than half are still alive.Six months after treatment, 41 percent still had a partial response (cancer shrunk at least in half) and 36 percent were in complete remission (no sign of disease).“The numbers are fantastic,” said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite. “These are heavily treated patients who have no other options.”One of his patients, 43-year-old Dimas Padilla of Orlando, was driving when he got a call saying his cancer was worsening, chemotherapy was no longer working, and there was no match to enable a second try at a stem cell transplant.“I actually needed to park … I was thinking how am I going to tell this to my mother, my wife, my children,” he said. But after CAR-T therapy last August, he saw his tumors “shrink like ice cubes” and is now in complete remission.“They were able to save my life,” Padilla said.Of the study participants, 13 percent developed a dangerous condition where the immune system overreacts in fighting the cancer, but that rate is lower than in some other tests of CAR-T therapy. The rate fell during the study as doctors got better at detecting and treating it sooner.Roughly a third of patients developed anemia or other blood-count-related problems, which Locke said were easily treated. And 28 percent had neurological problems such as sleepiness, confusion, tremor or difficulty speaking, but these typically lasted just a few days, Locke said.“It’s a safe treatment, certainly a lot safer than having progressive lymphoma,” and comparable to combination chemotherapy in terms of side effects, said the cancer institute’s Dr. Steven Rosenberg, who had no role in Kite’s study. The first lymphoma patient Rosenberg treated this way, a Florida man, is still in remission seven years later.There were no cases of swelling and fluid in the brain in this or any other study testing Kite’s treatment, company officials said. That contrasts with Juno Therapeutics, which has had a CAR-T study put on hold twice after five patient deaths due to this problem.Company officials would not say what the treatment might cost, but other types of immune system therapies have been very expensive. It’s also being tested for some other types of blood cancer.___Online:Lymphoma info: https://seer.cancer.gov/statfacts/html/nhl.htmlCAR-T therapy: https://www.cancer.gov/about-cancer/treatment/research/car-t-cellsGene therapy: https://ghr.nlm.nih.gov/primer/therapy/availability___Marilynn Marchione can be followed at https://twitter.com/MMarchioneAP .